BRPI0908919A2 - Derivados de 2-aminoquinolina como antagonistas do receptor 5-ht5a - Google Patents

Derivados de 2-aminoquinolina como antagonistas do receptor 5-ht5a

Info

Publication number
BRPI0908919A2
BRPI0908919A2 BRPI0908919-5A BRPI0908919A BRPI0908919A2 BR PI0908919 A2 BRPI0908919 A2 BR PI0908919A2 BR PI0908919 A BRPI0908919 A BR PI0908919A BR PI0908919 A2 BRPI0908919 A2 BR PI0908919A2
Authority
BR
Brazil
Prior art keywords
receptor antagonists
aminoquinoline derivatives
ht5a receptor
ht5a
aminoquinoline
Prior art date
Application number
BRPI0908919-5A
Other languages
English (en)
Inventor
Sabine Kolczewski
Claus Riemer
Olivier Roche
Lucinda Steward
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0908919A2 publication Critical patent/BRPI0908919A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0908919-5A 2008-03-12 2009-03-03 Derivados de 2-aminoquinolina como antagonistas do receptor 5-ht5a BRPI0908919A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08152618 2008-03-12
PCT/EP2009/052484 WO2009112395A1 (en) 2008-03-12 2009-03-03 2-aminoquinolines as 5-ht5a receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0908919A2 true BRPI0908919A2 (pt) 2015-07-28

Family

ID=40506484

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908919-5A BRPI0908919A2 (pt) 2008-03-12 2009-03-03 Derivados de 2-aminoquinolina como antagonistas do receptor 5-ht5a

Country Status (11)

Country Link
US (1) US8350028B2 (pt)
EP (1) EP2254666A1 (pt)
JP (1) JP2011513452A (pt)
KR (1) KR20100112199A (pt)
CN (1) CN101959557A (pt)
AU (1) AU2009224760A1 (pt)
BR (1) BRPI0908919A2 (pt)
CA (1) CA2716907A1 (pt)
IL (1) IL207438A0 (pt)
MX (1) MX2010009820A (pt)
WO (1) WO2009112395A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010003001A (es) * 2007-09-27 2010-04-01 Hoffmann La Roche Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a.
CN101959876A (zh) * 2008-03-05 2011-01-26 弗·哈夫曼-拉罗切有限公司 2-氨基喹啉类化合物
AU2009221294A1 (en) * 2008-03-07 2009-09-11 F. Hoffmann-La Roche Ag 2-Aminoquinolines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2468015A1 (en) * 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
CA2518398A1 (en) * 2003-03-10 2004-09-23 Schering Corporation Heterocyclic kinase inhibitors: methods of use and synthesis
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
EP1917245A1 (de) * 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
JP5111509B2 (ja) * 2006-09-28 2013-01-09 エフ.ホフマン−ラ ロシュ アーゲー 5−ht結合性を有するキノリン誘導体
MX2010003001A (es) * 2007-09-27 2010-04-01 Hoffmann La Roche Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a.

Also Published As

Publication number Publication date
CA2716907A1 (en) 2009-09-17
KR20100112199A (ko) 2010-10-18
CN101959557A (zh) 2011-01-26
MX2010009820A (es) 2010-10-15
IL207438A0 (en) 2010-12-30
JP2011513452A (ja) 2011-04-28
US8350028B2 (en) 2013-01-08
US20090233927A1 (en) 2009-09-17
AU2009224760A1 (en) 2009-09-17
EP2254666A1 (en) 2010-12-01
WO2009112395A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0923512A2 (pt) antagonistas de receptores de ácido lisofosfatídico
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
BRPI1013821A2 (pt) piridinas substituídas como antagonistas de ccr3.
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
EP2350060A4 (en) Melanocortin receptor AGONISTS
BR112012010502A2 (pt) derivados de benzimidazol-imidazol
BRPI0812981A2 (pt) Derivados de piperidina úteis como antagonistas dos receptores de orexina
ATE540942T1 (de) Imidazolderivate als ccr2-rezeptor-antagonisten
DK2401269T3 (da) Indolderivater som crth2-receptorantagonister
CO6811856A2 (es) Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0814767A2 (pt) Derivados de monoamida como antagonistas do receptor de orexina
EP2365749A4 (en) Quinolone NEURO PEPTIDE-S-Receptor Antagonists
BRPI0814806A2 (pt) Pirazinas substituídas como antagonistas de cb1
BRPI1007369A2 (pt) derivados de di-hidroquinolinona
BRPI0720078A2 (pt) 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
CU23857B1 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.